ThromboGenics acquires rights to eye treatment technology
BRUSSELS (Reuters) - Belgian biopharmaceutical company ThromboGenics said on Thursday it had entered into an agreement with British peer Bicycle Therapeutics to develop and launch new drugs to treat opthalmic diseases.
ThromboGenics said it would seek to use Bicycle's peptides, tiny particles which could be used to treat diabetic macular edema, a leading cause of vision loss in adults, particularly those with diabetes.
ThromboGenics, which specializes in eye treatment, will pay Bicycle an undisclosed upfront fee and payments related to development and regulatory milestones.
(Reporting By Philip Blenkinsop)
- Protesters fell Lenin statue, tell Ukraine's president 'you're next'
- Four dead in apparent Connecticut murder-suicide
- South Korea expands air defense zone to partially overlap China's |
- Singer Susan Boyle reveals she has Asperger's syndrome: paper
- Winter storm pushes up U.S. East Coast after deep-freeze in the South
Nelson Mandela: 1918 - 2013
Reuters looks at the life and times of Nelson Mandela, an icon of peace and reconciliation who came to embody the struggle for justice around the world. Video